Life Sciences

  • December 18, 2025

    Trump Orders Loosening Of Federal Restrictions On Marijuana

    President Donald Trump on Thursday announced that his administration would instruct federal agencies to loosen restrictions on cannabis via executive order, a historic acknowledgment from the executive branch that the drug has recognized medical uses.

  • December 17, 2025

    Sterne Kessler Draws Scolding, But No Sanctions Midtrial

    A Delaware federal judge said Wednesday she wasn't happy with the tone used by attorneys defending a radiopharmaceutical company from patent infringement claims and that she does not condone the attorneys' conduct in improperly contacting three inventors named in a patent at issue, but she declined to issue the severe sanction of kicking them off the case.

  • December 17, 2025

    Shutdown Deal Bars Federal Firings Until Feb., Judge Says

    A California federal judge said Wednesday she'll grant a preliminary injunction barring layoffs of federal workers from several agencies before Jan. 30, saying legislation that ended the government shutdown prohibits the layoffs, but she added she might pause her order while the government appeals.

  • December 17, 2025

    Conn. Zantac Injury Bellwether Trials Set To Begin In 2028

    Bellwether trials in lawsuits against drugmaker Boehringer Ingelheim Pharmaceuticals Inc. over the side effects of Zantac are set to begin in Connecticut state court in March 2028, according to a court order.

  • December 17, 2025

    Great American Says Cryo Unit Co. Hid Facts In Getting Policy

    Insurer Great American has gone to California federal court asserting that it doesn't owe coverage to a cryotherapy unit seller for an underlying lawsuit involving an alleged injury in a hyperbaric chamber at the company's subsidiary, arguing that the cryotherapy company never told the insurer it had a subsidiary.

  • December 17, 2025

    Doctors Not Harmed By CDC's Vaccine Guidance, Feds Say

    The federal government argued Wednesday that doctors lack standing to challenge the overhaul of a key federal vaccine committee that has since downgraded the COVID-19 shot, saying healthcare providers haven't been harmed by the policy shifts.

  • December 17, 2025

    Adderall Telehealth Startup Indicted After CEO's Conviction

    A San Francisco grand jury has indicted California telehealth startup Done Global, alleging it had a role in a healthcare fraud conspiracy that involved submitting false claims to government health programs and distributing $100 million in Adderall and other drugs through subscription services, federal prosecutors said Wednesday. 

  • December 17, 2025

    The Spiciest Quotes From Massachusetts Courts In 2025

    Massachusetts courts were replete with high-stakes cases throughout the year, with memorable lines from lawyers and judges alike, including jabs, thoughtful reflections and one defendant "blinded by love."

  • December 16, 2025

    Dana-Farber To Pay $15M To Resolve Fraud Allegations

    Dana-Farber Cancer Institute will pay $15 million to settle allegations that its researchers used inaccurate images in grant applications and research articles, the U.S. Department of Justice announced Tuesday.

  • December 16, 2025

    Ex-NIAID Director Claims Retaliation in Trump Admin Suit

    The former director of the National Institute of Allergy and Infectious Diseases filed suit in Maryland federal court on Tuesday alleging Trump administration appointees violated her constitutional rights by illegally terminating her employment and that she cannot expect her claims to be fairly heard by the "undermined" U.S. Office of Special Counsel.

  • December 16, 2025

    Samsung Wants ITC To Consider Oura Smart Ring IP Fight

    Samsung has expanded its legal battle with Oura over patents covering biometric-tracking wearable technologies, telling the U.S. International Trade Commission that Oura's smart rings infringe a set of four patents owned by Samsung.

  • December 16, 2025

    PE-Backed Medline Prices Long-Awaited $6.3B IPO

    Private equity-backed medical supplies giant Medline, guided by Simpson Thacher & Bartlett LLP, on Tuesday priced an upsized initial public offering, raising $6.26 billion in what will be the largest IPO of 2025 just weeks before year-end.

  • December 16, 2025

    Ultrahuman Loses Bids To Halt ITC Order In Oura Patent Case

    The U.S. International Trade Commission and the Federal Circuit have both denied requests by Ultrahuman to stay ITC orders barring imports of its smart rings found to infringe an Ouraring patent, turning aside Ultrahuman's arguments that the orders are too broad.

  • December 16, 2025

    DOD To Reevaluate Discharges Over COVID Vax Refusal

    The U.S. Department of Defense said on Tuesday that Secretary of Defense Pete Hegseth ordered a reevaluation of the discharge status of service members who were involuntarily removed from the military after they refused to receive the COVID-19 vaccine. 

  • December 16, 2025

    Vax Skeptics Cite High Court In New Challenge To NY Mandate

    A vaccine skepticism advocacy group once tied to Secretary of Health and Human Services Robert F. Kennedy Jr. is revamping its fight against New York's school vaccination mandate, arguing recent activity by the U.S. Supreme Court necessitates a fresh analysis.

  • December 16, 2025

    PTAB Cuts X-Ray Patent Claims After Fed. Circ. Remand

    The Patent Trial and Appeal Board has found that three claims that Sigray Inc. challenged in a Carl Zeiss X-Ray Microscopy Inc. X-ray imaging patent were invalid after the Federal Circuit told it to take another look at the claims.

  • December 16, 2025

    Va. Judge Advances Most Claims In Stelara Antitrust Case

    A Virginia federal judge has allowed health insurer CareFirst's anticompetition and patent fraud claims against Johnson & Johnson to move forward in a case alleging anticompetitive behavior in relation to the immunosuppressive drug Stelara, while letting the pharmaceutical giant escape some claims of misrepresentation.

  • December 16, 2025

    Trump Executive Order Calls Fentanyl A 'WMD'

    President Donald Trump has declared fentanyl a "weapon of mass destruction," according to an executive order that explicitly calls on the military to respond to "chemical incidents in the homeland."

  • December 16, 2025

    The Most Important Healthcare And Life Science Deals Of 2025

    Attorneys taking stock of 2025 spoke to Law360 about the most important deals of the year, including Pfizer’s high-profile acquisition of Metsera and transactions in outpatient services and gene therapy.

  • December 16, 2025

    Trends That Shaped Healthcare Dealmaking In 2025

    With 2025 coming to a close, Law360 Healthcare Authority asked attorneys focused on healthcare deals for their take on the trends that influenced dealmaking over the last 12 months.

  • December 16, 2025

    Merck Sued Over Time Rounding, OT Averaging At NC Plant

    A Merck manufacturing facility in North Carolina rounded workers' time to short them on pay, averaged out overtime across two weeks and fired an operator technician because of his sleep apnea, the worker told a federal court in a proposed class and collective action against the pharmaceutical giant.

  • December 16, 2025

    Jury Says Magnolia Medical Is Owed $1.6M After Patent Trial

    A Delaware federal jury on Tuesday morning found that Magnolia Medical Technologies Inc. is entitled to nearly $1.6 million after Kurin Inc. infringed its patents tied to devices meant for drawing blood.

  • December 16, 2025

    5 Big Litigation Developments Out Of Georgia In 2025

    It was a busy year for courts in Georgia, with a federal judge ordering the state's corrections system to continue providing hormone therapy to transgender people in prison, and prosecutors deciding to drop the historic racketeering case against President Donald Trump and his allies. Here, Law360 recaps the biggest legal developments to come out of Peach State courts in 2025.

  • December 16, 2025

    Another Dechert IP Atty Leaves, This Time For Morgan Lewis

    Morgan Lewis LLP has added another departing member of the Dechert LLP intellectual property team, who joins the firm in Boston after Dechert's global intellectual property practice co-chair, two partners, and a total of 30 professionals moved to Cooley LLP last week.

  • December 16, 2025

    Medical Device Maker Zynex Hits Ch. 11 With Sale Plans

    Zynex Inc., a pain management medical device maker, filed for bankruptcy protection in Texas with at least $66.7 million in debt and plans to sell the business backed by a stalking horse bid from its creditors.

Expert Analysis

  • Vanda Ruling Opens Door For Contesting FDA Drug Denials

    Author Photo

    The D.C. Circuit's recent decision in Vanda Pharmaceuticals v. U.S. Food and Drug Administration creates new opportunities and considerations for drug companies navigating the FDA approval process, establishing that litigation is an option when the FDA refuses to hold a hearing, say attorneys at Polsinelli.

  • Series

    Law School's Missed Lessons: Mastering Time Management

    Author Photo

    Law students typically have weeks or months to prepare for any given deadline, but the unpredictability of practicing in the real world means that lawyers must become time-management pros, ready to adapt to scheduling conflicts and unexpected assignments at any given moment, says David Thomas at Honigman.

  • Rare Del. Oversight Ruling Sends Governance Wake-Up Call

    Author Photo

    An unusual ruling from the Delaware Court of Chancery recently allowed Caremark oversight claims to proceed against former executives of a company previously known as Teligent, sending a clear reminder that boards and officers must actively monitor and document oversight efforts when addressing mission-critical risks, say attorneys at WilmerHale.

  • How Hyperlinks Are Changing E-Discovery Responsibilities

    Author Photo

    A recent e-discovery dispute over hyperlinked data in Hubbard v. Crow shows how courts have increasingly broadened the definition of control to account for cloud-based evidence, and why organizations must rethink preservation practices to avoid spoliation risks, says Bree Murphy at Exterro.

  • Pharma Copay Programs Raise Complex Economic Questions

    Author Photo

    The growing prevalence of copay accumulator and maximizer programs in the pharmaceutical industry is drawing increased scrutiny from patients, advocacy groups, lawmakers and courts, bringing complex questions about how financial responsibility for prescription drug purchases is determined and complicating damages assessments in litigation, say analysts at Analysis Group.

  • State False Claims Acts Can Help Curb Opioid Fund Fraud

    Author Photo

    State versions of the federal False Claims Act can play an important role in policing the misuse of opioid settlement funds, taking a cue from the U.S. Department of Justice’s handling of federal fraud cases involving pandemic relief funds, says Kenneth Levine at Stone & Magnanini.

  • Beaming Up Lessons From William Shatner's Failed Patent Bid

    Author Photo

    In a tale that boldly goes where few celebrity inventors have gone before, William Shatner's unsuccessful attempt to patent a smartphone file organization system offers insights about potential pitfalls to avoid in patent applications, say attorneys at King & Spalding.

  • The Pros And Cons Of Levying Value-Based Fees On Patents

    Author Photo

    The potential for a recurring, value-based maintenance fee on patents, while offering some benefits, raises several complications, including that it would likely exceed the U.S. Patent and Trademark Office's statutory authority and reduce research and development activities in the U.S., says Sandip Patel at Marshall Gerstein.

  • Series

    Writing Musicals Makes Me A Better Lawyer

    Author Photo

    My experiences with writing musicals and practicing law have shown that the building blocks for both endeavors are one and the same, because drama is necessary for the law to exist, says Addison O’Donnell at LOIS Law.

  • Between The Lines Of EPO's Adoption Of Color Drawings

    Author Photo

    The European Patent Office's decision to accept patent drawings in color starting in October may enhance clarity in technical disclosures and streamline the examination process, and could also enable new patent filing strategies for international applicants, say attorneys at Miller Canfield.

  • What Prop 65 Ruling Means For Cosmetics, Personal Care Biz

    Author Photo

    A California federal court's recent decision on Proposition 65 warnings is good news for companies in the cosmetics and personal care space, as it will relieve businesses of the need to apply such warnings to products containing titanium dioxide and likely stop a wave of pending failure-to-warn litigation, say attorneys at Morgan Lewis.

  • Series

    Adapting To Private Practice: From Va. AUSA To Mid-Law

    Author Photo

    Returning to the firm where I began my career after seven years as an assistant U.S. attorney in Virginia has been complex, nuanced and rewarding, and I’ve learned that the pursuit of justice remains the constant, even as the mindset and client change, says Kristin Johnson at Woods Rogers.

  • 2 Fed. Circ. Rulings Underscore Patent Prosecution Pitfalls

    Author Photo

    Two recent patent decisions from the Federal Circuit, overturning significant judgments, serve as reminders that claim modifications and cancellations may have substantive effects on the scope of other claims, and that arguments distinguishing prior art and characterizing claims may also limit claim scope, say attorneys at Morgan Lewis.

  • Rebutting Price Impact In Securities Class Actions

    Author Photo

    Defendants litigating securities cases historically faced long odds in defeating class certification, but that paradigm has recently begun to shift, with recent cases ushering in a more searching analysis of price impact and changing the evidence courts can consider at the class certification stage, say attorneys at Katten.

  • 7 Document Review Concepts New Attorneys Need To Know

    Author Photo

    For new associates joining firms this fall, stepping into the world of e-discovery can feel like learning a new language, but understanding a handful of fundamentals — from coding layouts to metadata — can help attorneys become fluent in document review, says Ann Motl at Bowman and Brooke.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.